Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

"* After 2 cycles, patients with progressive disease or relapse (a clear progression with at least \>20% bone marrow blasts and an increase of at least 50% from prior biopsy) should be removed from protocol and proceed to salvage treatment according to center preference~* Transplant eligible patients who achieve CR, CRc, or CRi, after 3 cycles with a suitable donor will proceed to conditioning regimen and transplant~* Transplant eligible patients with PR after 3 cycles may be removed from protocol and proceed to salvage treatment according to center preference~* Transplant eligible patients with a suitable donor who achieve mLFS, CR, CRc, or CRi, may proceed to transplant after at 3 cycles~* Transplant ineligible patients with (CR, CRc or CRi, PR) will continue on maintenance doses~* Transplant ineligible patient with SD after cycle 4 may be removed from protocol and proceed to alternative treatment or continue on protocol according to treating physician's preference."

"* Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression or relapse~* Biopsy/aspirate on Cycle 1 Day 10 is for participants enrolled at Washington University only~* Biopsy/aspirate on Cycle 2 Day 28 is at the discretion of the treating physician"

-Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression/Relapse

"* Optional but if refuse skin biopsy then participant can provided buccal swab~* There is no required time frame for this sample - it may have been collected months or even years prior to the first dose of decitabine~* If WBC at time of enrollment is \>30,000/µl, skin biopsy should be collected at the time of C1D28 bone marrow biopsy or thereafter"

-Baseline (if skin biopsy declined) and Cycle 2 Day 28